Comparative Pharmacology
Head-to-head clinical analysis: GASTROCROM versus NASALCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROCROM versus NASALCROM.
GASTROCROM vs NASALCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
Cromolyn sodium stabilizes mast cells by inhibiting the release of histamine and other mediators of inflammation from sensitized mast cells. The exact molecular mechanism is not fully understood but may involve inhibition of calcium ion influx into mast cells.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
One spray (5.2 mg) into each nostril 3-4 times daily (maximum 6 times daily).
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Terminal elimination half-life is 1-2 hours; clinically, due to local mast cell stabilization, systemic levels do not correlate with effect.
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Primarily unchanged drug; renal excretion accounts for ~90% of elimination, with minor biliary/fecal excretion (<5%).
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer